Other substances

Velpatasvir

A hepatitis C virus NS5A inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
15
 AI-suggested references
0
 Clinical trials

General information

Velpatasvir on PubChem

Synonyms

ZINC203686879

 

Structure image - Velpatasvir

C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC

Supporting references

Link Tested on Impact factor Notes Publication date
In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)
TMPRSS2 Small molecule In silico 		in silico 3.62

Predicted to inhibit the host’s TMPRSS2 protease.

 Mar/26/2021

AI-suggested references

Link Publication date
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Mar/03/2022
Interaction of the renin inhibitor aliskiren with the SARS-CoV-2 main protease: a molecular docking study.
Sep/13/2021
In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Mar/26/2021
A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction
May/17/2021
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach
Feb/04/2020
Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Jan/24/2021
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
Mar/30/2021
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
Jul/06/2020
Nucleotide analogues as inhibitors of SARS-CoV Polymerase
Oct/31/2020
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Nov/20/2021
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates
Feb/21/2020
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
Apr/17/2020
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial
Jun/30/2020
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Apr/29/2020
Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
Nov/10/2020
Export (.csv)